T-cell and B-cell perturbations identify distinct differences in HIV-2 compared with HIV-1-induced immunodeficiency by Hønge, Bo L et al.
 
  
 
Aalborg Universitet
T-cell and B-cell perturbations identify distinct differences in HIV-2 compared with HIV-
1-induced immunodeficiency
Hønge, Bo L; Petersen, Mikkel S; Jespersen, Sanne; Medina, Candida; Té, David D S;
Kjerulff, Bertram; Engell-Sørensen, Thomas; Madsen, Tina; Laursen, Alex L; Wejse,
Christian; Krarup, Henrik; Møller, Bjarne K; Erikstrup, Christian; Bissau HIV Cohort study
group
Published in:
AIDS
DOI (link to publication from Publisher):
10.1097/QAD.0000000000002184
Publication date:
2019
Document Version
Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
Hønge, B. L., Petersen, M. S., Jespersen, S., Medina, C., Té, D. D. S., Kjerulff, B., Engell-Sørensen, T.,
Madsen, T., Laursen, A. L., Wejse, C., Krarup, H., Møller, B. K., Erikstrup, C., & Bissau HIV Cohort study group
(2019). T-cell and B-cell perturbations identify distinct differences in HIV-2 compared with HIV-1-induced
immunodeficiency. AIDS, 33(7), 1131-1141. https://doi.org/10.1097/QAD.0000000000002184
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
AIDS, Publish Ahead of Print 
DOI: 10.1097/QAD.0000000000002184 
 
Title: T and B-cell perturbations identify distinct differences in HIV-2 compared with 
HIV-1 induced immunodeficiency 
Running head: T and B-cell phenotypes in HIV-2 infection 
Bo L Hønge1,2*, Mikkel S Petersen2, Sanne Jespersen1,3, Candida Medina4, David DS Té4, 
Bertram Kjerulff2, Thomas Engell-Sørensen1,3, Tina Madsen1,3, Alex L Laursen3, Christian 
Wejse1,3,6, Henrik Krarup7, Bjarne K Møller2, Christian Erikstrup2 for the Bissau HIV Cohort 
Study Group. 
1. Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau. 
2. Department of Clinical Immunology, Aarhus University Hospital, Denmark 
3. Department of Infectious Diseases, Aarhus University Hospital, Denmark.  
4. National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.  
5. National Public Health Laboratory, Bissau, Guinea-Bissau. 
6. GloHAU, Center for Global Health, School of Public Health, Aarhus University, Denmark 
7. Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, 
Denmark 
 
*Corresponding author  
Bo Langhoff Hønge  
Department of Clinical Immunology, Aarhus University Hospital 
Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark 
Telephone: +45 23718870, Fax: +45 78455015 
Email: bohonge@gmail.com 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Abstract 
Background 
For unknown reasons, HIV-2 is less pathogenic than HIV-1, and HIV-2 induced 
immunodeficiency may be different from that caused by HIV-1. Previous immunological 
studies have hinted at possible shifts in both T and B-cell subsets, which we aimed to 
characterize further. 
Methods 
From an HIV clinic in Guinea-Bissau, 63 HIV-2, 83 HIV-1, and 26 HIV negative participants 
were included. All HIV infected participants were ART naïve. The following cell subsets 
were analysed by flow cytometry; T cells (maturation and activation), regulatory T cells, and 
B cells (maturation and activation). 
Results 
After standardizing for sex, age, and CD4+ T cell count HIV-2 had 0.938 log10 copies/mL 
lower HIV RNA levels than the HIV-1 infected patients. Whereas T-cell maturation and 
regulatory T-cell profiles were similar between patients, HIV-2 infected patients had higher 
proportions of CD8+CD28+ and lower proportions of CD8+PD-1+ T cells than HIV-1 
infected patients. This finding was independent of HIV RNA levels. HIV-2 was also 
associated with a more preserved proportion of naïve B cells. 
Conclusion 
HIV-2 is characterized by lower viral load, and lower T-cell activation, which may account 
for the slower disease progression. 
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Introduction 
With an estimated 1-2 million people infected worldwide, HIV-2 is mostly found in West 
Africa and countries with historical relations to West Africa, such as Portugal and France 
[1,2]. Early surveys performed in the capital of Guinea-Bissau during the late 1980´s report a 
prevalence of 9% among adults [3]. Since then, the HIV-2 prevalence has declined and been 
surpassed by HIV-1 [4–6]. 
Although HIV-1 and HIV-2 are structurally similar, there is only 30-60% genetic similarity 
on a nucleic acid basis [7]. Also, viral load is usually lower in HIV-2 compared with HIV-1 
infected patients, and a large proportion of HIV-2 infected patients has undetectable viral 
load [8,9]. This may explain the relatively lower transmissibility of HIV-2 and that many 
HIV-2 infected individuals progress more slowly towards AIDS. On average, HIV-2 
infection advances to cause AIDS in 25-30 years [1,3,10–13]. The clinical manifestation of 
HIV-2-induced AIDS closely resembles that of HIV-1 [14]. For HIV-2 infected individuals 
with undetectable viral loads, the mortality rate is similar to that of the background 
population, but viremic individuals still have an excess mortality [12,15]. 
HIV-2 infected patients with normal CD4+ T-cell counts or low viral load have lower rates of 
T-cell activation compared with HIV-1 infected patients [16,17]. But during disease 
progression, the T-cell perturbations are very similar between HIV-1 and HIV-2 infected 
patients [17,18]. Although HIV-2 infected patients also experience a progressive loss of 
memory B-cells [19], a characteristic feature of HIV-2 infection is the development of 
broadly neutralizing antibodies [20]. 
To further understand the importance of HIV-2 RNA levels and immune perturbations, we 
compared immune subsets in HIV-1 and HIV-2 infected patients, and HIV negative 
individuals. 
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Material and methods 
Setting and study population 
During February 2016 – September 2017, we enrolled HIV infected patients at the HIV clinic 
situated at Hospital Nacional Simão Mendes, in the capital Bissau, Guinea-Bissau. All 
included patients were ART naïve and attended the clinic for a routine blood sampling in 
accordance with the national guidelines. The clinic has been described previously [21,22]. 
Individuals testing negative for HIV at the clinic were invited to participate as an HIV 
negative control group. These individuals may be regarded as high-risk seronegatives.  
Sample collection 
Venous blood samples were collected in CPT vacutainers containing sodium citrate/Ficoll 
(Becton Dickinson, New Jersey, United States). Within 4 hours, samples were transported to 
the reference laboratory, National Public Health Laboratory, and processed. After shipment to 
Denmark, samples were thawed according to an optimized protocol [23]. Further description 
of the sample handling is available in the supplementary section. 
Flow cytometric analysis 
PBMCs were stained in four different panels: T-cell maturation, activation and regulation, 
and B-cell maturation/activation (presented elsewhere). Definition of the maturation stages 
used for both T and B cells has been published previously [24,25]. The staining process is 
described in the supplementary section. 
Samples were analyzed on a Sony Spectral Cell Analyzer SP6800 (Sony Corporation, Tokyo, 
Japan) flow cytometer. The software SP6800 version 1.6.3.7151 was used for acquisition and 
spectral unmixing (weighted least-squares algorithm). Cell population gating was performed 
on unmixed data in FlowJo v.10.4 (FlowJo LLC, Ashland, USA) as presented elsewhere. 
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HIV diagnosis and HIV type discrimination 
 
HIV screening was performed using Determine HIV-1/2 (Abbott Laboratories, Tokyo, 
Japan). HIV Confirmation and HIV type discrimination was performed using ImmunoComb 
HIV 1/2 BiSpot (Orgenics, Yavne, Israel) and First Response HIV 1-2.0 Card Test (Premier 
Medical Corporation Ltd, Kachigam, India). Patients typed with First Response, and patients 
typed HIV-1/2 dual reactive with ImmunoComb, had confirmatory HIV typing performed 
with INNO-LIA HIV I/II Score (Fujirebio, Ghent, Belgium) [26]. 
 
HIV RNA measurements 
HIV-1 RNA was quantified on the Abbott m2000 platform (Abbott RealTime HIV 1, version 
9.00, Abbott Molecular Inc, Abbott Park, USA). As previously described [26] HIV-2 RNA 
was quantified using an in-house method. For both analyses, the detection limit was 50 
copies/mL. 
 
Statistical analyses 
Statistical analyses were performed in Stata IC 13.0 (Stata Corporation, Texas, USA). 
Patients with undetectable HIV RNA levels had imputed HIV RNA of 25 copies/mL 
equivalent to half the detection limit. Viremia was defined as HIV RNA above 100 
copies/mL. Chi squared tests were used for categorical variables. After checking for normal 
distribution, continuous variables were compared with either T-tests or Wilcoxon Rank-sum 
tests. Adjustments for sex, age, and CD4+ T-cell counts, and determining correlations, were 
performed by linear regression analysis. Maturation profiles of T and B cells were compared 
with the SPICE analysis. This tests whether the patient groups overall were different as a 
whole [27]. 
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Ethics 
Ethical approval was given by the ethics committee in Guinea-Bissau (No Ref. 061/2013) 
after the Danish committee had given consultative approval (case no. 1305362). Patient 
participation was voluntary, and signed consent forms were obtained from all included 
patients. For illiterate patients, fingerprint signatures were obtained. 
 
Results 
Characteristics of included patients 
We included 63 HIV-2 infected patients (47 viremic and 16 aviremic), 83 HIV-1, and 26 HIV 
negative controls. Sex distribution was similar between patient groups, and between patients 
and controls (Table 1). The HIV negative control group was younger than both HIV-2 
(p<0.001) and HIV-1 (p=0.003) infected patients, and the HIV-2 infected patients were older 
than the HIV-1 infected patients (p<0.001). Despite the higher age, HIV-2 infected patients 
had a higher median CD4+ T-cell count (351 cells/µL) compared with HIV-1 infected 
patients (217 cells/µL, p<0.001). CD4+ T-cell count was not measurered for the HIV 
negative controls. Among HIV-2 infected patients, those with aviremia tended to have higher 
CD4+ T cell count (p=0.085), but there was no difference in sex (p=0.165) or age (p=0.411). 
HIV RNA was lower for HIV-2 than for HIV-1 infected patients (p<0.001) – on average 
0.938 log10 copies/mL (95% CI: 0.286 – 1.591) after standardizing for differences in sex, age 
and CD4+ T-cell count. For both groups, HIV RNA correlated inversely with CD4+ T-cell 
count (Figure 1), but there was no difference in the correlation coefficients (p=0.886). 
Despite undetectable HIV-2 RNA (aviremia), 3/16 (19%) of the HIV-2 infected patients had 
CD4 cell count below 200 cells/µL. 
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T-cell maturation 
For the overall CD4+ T-cell maturation stage distribution we found no difference between 
HIV negative and HIV-2 infected patients (p=0.307), but HIV-2 infected patients presented 
with higher proportions of early differentiated T-cells compared with HIV-1 infected patients. 
Albeit, when stratified by CD4+ T-cell count (above/below 350 cells/µL) there was no 
difference in CD4+ T-cell maturation profiles (Supplementary Figure 1, 
http://links.lww.com/QAD/B456). 
 
For CD8+ T-cells (Figure 2), the HIV-2 infected patients differed significantly overall from 
both the HIV negative and the HIV-1 infected individuals (for both p<0.001). Early 
differentiated CD8+ T-cells (naïve, 1st antigen experienced, and 2nd antigen experienced) 
were relatively scarcer in HIV-2 infected patients compared with the HIV negative 
individuals, whereas 3rd and 4th antigen experienced T-cells constituted a relatively larger 
proportion. A similar pattern was observed for the HIV-1 infected patients with even fewer 
early stage, and more late stage, differentiated T-cells. 
 
When stratified by CD4+ T-cell count (Supplementary Figure 1, 
http://links.lww.com/QAD/B456) these differences diminished, and there was no overall 
difference between HIV-2 and HIV-1 for patients with CD4+ T cell count below 350 cells/µL 
(p=0.165). When comparing HIV negative individuals with HIV infected patients with CD4+ 
T-cell count above 349 cells/µL, there was lower proportions of naïve CD8+ T-cells for both 
groups of HIV infected patients – this proportion was even lower for HIV-1 compared with 
HIV-2 infected patients. 
 
T-cell activation 
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Compared with HIV negative individuals, the HIV-2 infected patients presented with higher 
proportions of CD4+PD-1+ T cells compared with HIV negative individuals (p=0.010), 
Supplementary Figure 2, http://links.lww.com/QAD/B456). HIV-1 was associated with a 
lower proportion of CD4+CD28+ T cells, and a higher proportion of CD4+CD38+, 
CD4+CTLA4+, and CD4+PD-1+ T cells. There was no differences between HIV-2 and HIV-
1 for CD4+ T-cell activation markers after adjusting for sex, age and CD4+ T-cell count 
(Supplementary Figure 3, http://links.lww.com/QAD/B456). 
 
For the CD8+ T cells, activation markers are presented in Supplementary Figure 4, 
http://links.lww.com/QAD/B456. Patient groups were stratified by CD4+ T-cell count 
above/below 350 cells/mL, and by viremic status for HIV-2. Both HIV-2 and HIV-1 infected 
patients had lower proportions of CD8+CD28+ T cells than the HIV negative individuals. 
This was also the case among HIV infected patients with CD4+ T-cell count above 349 
cells/µL, and for aviremic HIV-2 infected patients. Both HIV-2 and HIV-1 infected patients 
also had higher proportions of CD8+PD-1+ T cells compared with HIV negative individuals.  
 
When comparing HIV-2 and HIV-1 infected patients in Figure 3, we adjusted for sex, age 
and CD4+ T-cell count. Across CD4+ T-cell-levels HIV-2 infected patients had higher 
proportions of CD8+CD28+ and lower proportions of CD8+PD-1+ T cells. Proportions of 
these markers were stratified into naïve (CD45RA+) and memory (CD45RO+) CD8+ T cells 
(Supplementary Figure 5 and 6, http://links.lww.com/QAD/B456), and found that CD8+ T-
cell maturation did not influence the HIV type-specific differences for these markers. Finally, 
we tested proportions of CD8+CD28+ and CD8+PD-1+ T cells for correlation with HIV 
RNA levels. Both markers tended to be associated with HIV RNA levels (Supplementary 
Figure 7, http://links.lww.com/QAD/B456), but even after adjusting for sex, age, CD4+ T 
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cell count and viral load, HIV-2 infected patients had higher proportions of CD8+CD28+ 
(p=0.008) and lower levels of CD8+PD-1+ T cells (p=0.001). 
 
 
Regulatory T cells (Tregs) 
The proportion of Tregs (defined as CD3+CD4+FoxP3+ cells) were higher among HIV-1 and 
HIV-2 infected patients than among HIV negative individuals in the crude analysis, but there 
were no differences after adjustment for sex and age (Figure 4). For both HIV-2 and HIV-1 
infected patients a lower proportion of Tregs expressed CD25, and a higher proportion 
expressed CD49d. HIV-2 and HIV-1 infected patients were compared by adjusting for age, 
sex and CD4+ T cell count (Supplementary Figure 8, http://links.lww.com/QAD/B456), and 
there were no differences between groups. 
 
B-cell maturation and activation 
HIV-2 infected patients differed in their B-cell maturation profiles compared with the HIV 
negative individuals (p=0.012) and with the HIV-1 infected patients (p<0.001, 
Supplementary Figure 9, http://links.lww.com/QAD/B456). However, when stratifying by 
CD4+ T cell above 349 cells/µL most differences perished. Still, HIV-2 infected patients had 
higher proportions of naïve B-cells among patients with CD4+ T-cell count below 350 
cells/µL (p=0.001). 
 
As presented in Figure 5, proportions of the marker of functional impairment, CD21low, was 
greater in both HIV-1 and HIV-2 infected patients compared with the HIV negative 
individuals. Even aviremic HIV-2 infected patients, and those with CD4+ T-cell count above 
349 cells/µL had increased levels compared to the HIV negative individuals. When adjusting 
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for sex, age and  CD4+ T-cell count, there was no longer any difference between HIV-2 and 
HIV-1 infected patients (p=0.157) – Supplementary Figure 10, 
http://links.lww.com/QAD/B456. We found no differences in proportions of B cells with the 
activation marker CD80 between any groups. 
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Discussion  
In this cross-sectional study we compared T and B-cell perturbations in ART-naïve HIV 
infected and HIV-negative individuals from Guinea-Bissau. At similar CD4+ T-cell count 
levels, HIV-2 infected patients presented with almost 1-log10 lower levels of HIV RNA. 
Both HIV types were associated with depletion of early stage (naïve) CD8+ T cells and an 
increased proportion of T cells positive for activation markers. HIV-2 was associated with 
higher proportions of CD8+CD28+ and lower proportions of CD8+PD-1+ T cells than for 
HIV-1 even after adjusting for sex, age, CD4+ T-cell count, and HIV RNA levels. Both HIV-
1 and HIV-2 infected patients had perturbations in their Treg-profiles, but there were no 
differences between HIV types. HIV-2 infected patients had more preserved proportion of 
naïve B-cells than for HIV-1, but a similar high proportion of CD21low B cells. 
 
Similar to our findings, many previous studies have described lower HIV RNA levels in 
HIV-2 compared with HIV-1 infected individuals [8,9,16]. A relatively large proportion of 
our HIV-2 infected patients had detectable viral load, which may be explained by inclusion of 
patients at an HIV clinic rather than enrollment of participants from a general population 
survey. Patients attending the HIV clinic in Bissau often present with advanced disease 
progression [28], and the level of viral load, also correlate inversely with CD4+ T-cell count 
for HIV-2 infected patients [8]. We found that HIV-2 compared to HIV-1 infected patients 
had a viral load difference of almost 1-log10 difference after standardizing for sex, age, and 
CD4+ T-cell count. Even though aviremic HIV-2 infected individuals demonstrate a survival 
rate similar to the background population [15], we found 19% of the aviremic HIV-2 infected 
patients to have advanced disease progression with CD4+ T-cell counts below 200 cells/µL 
suggesting that these patients either progress with very little viral replication or that viral load 
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may be fluctuating over time. CD4 cell depletion (below 200 cells/µL) has also been 
described in a proportion of aviremic HIV-2 infected Portuguese patients [16]. 
 
In the Portuguese study [16], they also investigated T-cell maturation stage distribution in 
HIV-1 and HIV-2 infected patients but found no differences in proportions of naïve 
(CD45RA+CD62L+) and memory (CD45RO+) CD4+ or CD8+ T cells at given degrees of 
HIV disease progression. Although late-differentiated (CD45RO+CD27-) CD4+ cells were 
proportionally more frequent in HIV-1 compared with HIV-2 infected individuals, Buggert et 
al. conclude that maturation differentiation is not a hallmark that distinguishes HIV-2 from 
HIV-1 infection [29]. Direct comparisons between studies are complicated by different 
definitions of maturation subsets and study participant selection. These other studies [16,29] 
investigating T-cell maturation used a less stringent definition of memory T cells than the 
consensus definition applied in our study [25]. Factors other than HIV may affect T-cell 
maturation distribution, such as age. But as age can also be a proxy for disease duration, 
adjustment could blur a true association. Differences in T-cell maturation profiles may result 
from differences in T-cell turnover rates induced by immune activation [17,30]. However, T-
cell maturation profiles do not seem to differ between HIV-1 and HIV-2 at similar levels of 
CD4+ T-cell counts. 
 
Immune activation is closely linked to perturbations in T-cell maturation staging. Among 
Guinean police officers Buggert et al. found that HIV-2 compared to HIV-1 was associated 
with a lower proportion of activated (CD38+HLA-DR+) CD4+ T-cells [29]. Lower levels of 
immune activation in HIV-2 infection correspond well with previous studies describing a 
prolonged disease course on average, and as for HIV-1, CD38 expression also correlates with 
viral load in HIV-2 infection [18]. We also found a lower proportion of CD4+CD38+ and 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CD8+CD38+ T cells in the crude analyses, but after adjusting for sex, age and CD4+ T-cell 
count, there was no difference. Hence, the crude difference in proportions of CD38+ T cells 
was likely not an HIV-type-specific effect. 
 
The importance of CD8+ T cells in HIV-1 infection has been extensively investigated, but 
much less attention has been given to describing and understanding this lymphocyte subset in 
those with HIV-2 infection. CD28 is a costimulatory receptor, and binding of CD28 with it´s 
ligand CD80 on antigen-presenting cells results in a proliferatory signal, activates 
telemerases, and enhance T-cell migration/homing [31]. During HIV-1 infection, the 
proportion of CD8+ T cells lacking CD28 increase [32], and these CD8+CD28- T-cells are 
considered to be at the end-stage of replicative senescence [33]. We found that proportions 
CD8+CD28+ T cells correlated positively with CD4+ T-cell count for both HIV-1 and HIV-
2, but among HIV-2 infected patients there was a higher proportion of CD8+CD28+ T cells 
across CD4+ T-cell levels. This association remained even after adjusting for sex, age, CD4+ 
T-cell count and viral load. Khalid et al. found that Nef-mediated downregulation of CD28 
correlated with suppression of T-cell activation in viremic but not in aviremic HIV-2 infected 
individuals [34]. Two studies investigating HIV-2-specific T cells found higher proportions 
of CD8+CD28+ T-cells among individuals with HIV-2. This suggest that high proportions of 
CD8+CD28+ T cells are associated with viral control [35,36]. 
 
The programmed death-1 receptor (PD-1) is upregulated during HIV-1 infection and limits 
tissue damage by suppressing T-cell-receptor-CD28 mediated activation [37]. For HIV-1, 
reduced PD-1 expression on virus-specific CD8+ T cells correlates with viral control, and 
blockage of PD-1 results in enhanced HIV-specific proliferative response of CD8+ T cells 
[38,39]. These cells with high level expression of PD-1 are more functionally impared 
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compared to CD8+ T cells with lower PD-1 expression [40], and PD-1 expression is also 
reduced among patients on ART [41,42]. This suggests that a high viral load drives PD-1 
expression and cause functional exhaustion. Recently, is had been described that PD-1 is also 
involved in establishing and maintaining HIV latency [43]. In agreement with Tendeiro et al. 
[44], we found elevated proportions of PD-1 on CD8+ T cells in both HIV-1 and HIV-2 
infection compared to HIV negative individuals, and that HIV-2 infected patients had lower 
levels than for HIV-1. We extended this analysis by adjusting for sex, age, CD4+ T-cell 
count, and viral load. Still, HIV-2 was associated with lower proportions of CD8+PD-1+ T 
cells.  
 
Our results therefore suggest, that higher CD8+CD28 and lower CD8+PD-1 proportions of T 
cells are true hallmarks of HIV-2 infection distinguishing it from HIV-1. This may result in 
more effective CD8+ T-cell responses to better control viral replication and slow CD4+ T-
cell decline.  
 
A number of studies have investigated HIV-specific T-cell responses in HIV-2 and HIV-1 
infected individuals in attempts to understand the relatively lower pathogenicity of HIV-2 
[36,45–53]. The protein Gag is most immunogenic in HIV-2 infection and the specific T-cell 
response to this protein relates to the degree of viremia [45,50,52]. HIV-2 infected 
individuals also demonstrate a more broad and polyfunctional T-cell response, which may 
even have an effect against HIV-1 [49,51]. This could also partly explain a potential 
protective effect induced by HIV-2 against disease progression during subsequent HIV-1 
infection [54,55]. In contrast to HIV-1, a single HIV-2 epitope may induce a sufficient CD8+ 
T cell Gag-specific response [53]. And whereas CD8+ T cells in HIV-1 and HIV-2 infected 
subject are able to suppress R5 tropic viral strains equally, X4 viral replication is inhibited to 
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a larger extent during HIV-2 infection [48]. It is unknown why some individuals with HIV-2 
infection are able to generate these favorable immune responses and others are not, but 
certain genetic traits are likely to be part of the explanation. We have recently shown that 
specific HLA-alleles (HLA-B*58:01, HLA-DPB1*10:01, and HLA-DRB1*11:01) are 
associated with lower HIV-2 RNA levels [56]. 
 
Tregs function as immune suppressors that protect against tissue damage by promoting 
peripheral immune tolerance and decreasing cell activation. Chronic immune activation 
during HIV-1 infection induces expansion of the Treg subset, and these cells may inhibit the 
HIV-1-specific response, thereby favoring viral replication [57]. As HIV-2 infected 
individuals present with lower viral load, the relative proportion and features of Tregs could 
be expected to be different from patients with HIV-1. In this analysis we included the Treg 
surface marker CD49d. As CD49d+ Tregs produce IFN-γ and IL-17, they may be considered 
proinflammatory rather than immunosuppressive cells [58,59]. In Portuguese patients, Foxall 
et al. found similar levels of Tregs when comparing HIV-1 and HIV-2 infected patients, and 
as for HIV-1, frequency of Tregs increased with HIV disease progression in patients with 
HIV-2 [60]. We also found a similar pattern with equal proportions of Tregs for HIV-1 and 
HIV-2, and there was no difference in the Treg surface markers including CD49d. 
 
Only few studies have compared B-cell perturbations in HIV-2 and HIV-1 infected 
individuals. After stratifying by CD4 cell count, the HIV-2 infected patients with CD4+ T-
cell count below 350 cells/µL had larger proportions of naïve B-cells. B-cell imbalances have 
also been described by Tendeiro et al. who found that HIV-2 infected patients have more 
extensive depletion of memory B-cells than the HIV-1 infected and HIV negative 
counterparts, despite similar numbers of total B cells [19]. Depletion of memory B-cells was 
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furthermore associated with viremia for HIV-2, but not HIV-1 infected patients. Our results 
are thus in line with this previous study showing marked HIV-type specific differences 
during the disease course. 
 
To our knowledge, the CD21low B cell subset has not previously been investigated in HIV-2 
infected individuals. We found that the proportion of these impaired B cells was higher for 
both HIV-2 and HIV-1 infected patients, but without difference between patient groups. Even 
HIV-2 infected patients with undetectable viral load and patients with CD4+ T-cell count 
above 349 cells/µL had increased proportions of CD21low B cells compared to the HIV 
negative individuals. CD21low B cells have reduced responsiveness to B-cell stimuli and 
enhanced production of immunoglobulins, which may explain hypergammaglobulinemia 
during HIV infection [61]. Indeed, marked HIV-type specific differences in antibody 
production have been reported. HIV-2 infected individuals have high tites of neutralizing 
antibodies, although neither the level of heterologous nor autologous antibodies are 
associated with greater control of HIV-2 [62]. Nevertheless, the neutralizing antibodies from 
HIV-2 infected individuals have a broader effect and are more potent than antibodies derived 
from HIV-1 infected individuals [63,64]. 
 
Conclusions 
We here present a large study describing both T and B-cell phenotypes in patients from the 
center of the epidemic. In combination with lower viral load, HIV-2 infected patients 
presented with higher proportions of CD8+CD28+ and lower proportions of CD8+PD-1+ T 
cells. HIV-2 was also associated with higher proportions of naïve B-cells. These findings add 
to the current knowledge of immunological differences in HIV-2 and HIV-1 infection, and 
may partly explain why HIV-2 infected patients have slower disease progression. 
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Table 1: Patient characteristics by HIV type and with HIV-2 infected patients stratified by 
viremia. Results are counts with percentages, or medians with interquartile ranges (IQR). 
  HIV neg HIV-2 HIV-1 
  all aviremic* viremic*  all 
Number (females/males) 26 16 47 83 
(17 / 9) (12 / 4) (26 / 21) (56 / 27) 
Age, years (IQR) 30 43 49 39 
(25 - 38) (40 - 53) (39 - 58) (31 - 49) 
CD4 T-cell count, cells/µL 
(IQR) NA 557 324 217 
NA (302 - 875) (180 - 574) (97 - 395) 
% CD4 T cells (IQR) 63.4 45.0 36.0 18.2 
(55.7 - 67.5) (26.4 - 57.1) (19.4 - 46.3) (8.3 - 26.6) 
HIV-1 RNA copies/mL 
(IQR) NA NA NA 127.836 
NA NA NA 
(27,665 - 
391,516) 
HIV-2 RNA copies/mL 
(IQR) NA <100 30,000 NA 
  NA - 
(2,600 - 
260,000) NA 
Viremia defined as HIV RNA > 100 copies/mL 
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Figure 1: HIV RNA levels by CD4+ T cell count for HIV-2 and HIV-1 infected patients. RC 
= regression coefficient. 
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Figure 2: SPICE analysis of T cell maturation distribution. #1 HIV negative, #2 HIV-1, #3 
HIV-2. CD8+ T-cell maturation. AG: antigen experienced. #: significant difference between 
groups. 
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Figure 3: T cell activation markers on CD8+ T-cells in HIV-2 compared to HIV-1 infected 
patients. P-values for difference in proportions of CD8+ T-cells activation markers calculated 
with linear regression analyses with adjustment for age, sex and CD4+ T cell count. 
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Figure 4: Regulatory (CD3+CD4+FoxP3+) T cells in HIV negative, HIV-1 and HIV-2 
infected individuals. Groups were compared with Wilcoxon ranksum tests and crude p-values 
are presented. P-values significant after linear regression analyses adjusting for sex and age 
are noted with a. 
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Figure 5: Proportion of B-cells without the surface marker CD21 (CD21low) on PBMCs 
from HIV negative individuals, HIV-1 and HIV-2 infected patients. Data presented with 
medians and interquartile range bars. Wilcoxon ranksum tests were used to compare groups, 
and adjustment (a) for sex and age were performed using linear regression analyses. 
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